Xeris Pharmaceuticals | XERS - Betriebsaufwand

Aktienkurs
6.05
Täglich Wechseln
0.10 1.68%
Monatlich
14.15%
Jährlich
40.37%
Q2 Prognose
5.92




Betriebsaufwand Veränderung Datum
Celltrion KRW 724.99B 6B 2025-09
Cspc Pharmaceutical CNY 5.91B 512.77M 2025-12
Deva Holding AS TRY 1.35B 178.26M 2023-09
Dianthus Therapeutics USD 69.82M 29.14M 2025-12
Divis Laboratories Ltd INR 18.32B 1.08B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Kangmei Pharma CNY 1.39B 144.29M 2025-09
Knight Therapeutics CAD 126.9M 8.29M 2025-12
Laboratorios Farma EUR 313.62M 17.98M 2023-12
Malin Corporation EUR 1.1M 400K 2024-12
Medical Developments International AUD 21.61M 11.59M 2025-12
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neuren Pharmaceuticals AUD 25.23M 16.54M 2025-12
Organigram Holdings CAD 83.66M 24.44M 2025-12
Ovoca Bio EUR 1.16M 4.48M 2025-06
Pacira USD 193.68M 27.32M 2025-12
Perrigo USD 1.03B 75.3M 2025-12
Pharma Mar EUR 46.87M 7.24M 2025-12
Qiagen NV USD 418.54M 23.25M 2025-12
Sartorius EUR 738.4M 22.4M 2026-03
Sino Biopharmaceutical CNY 12.39B 1.26B 2025-06
Supernus Pharmaceuticals USD 197.75M 54.54M 2025-12
Tilray USD 237.52M 17.34M 2025-09
Zealand Pharma A/S 775.97M 265.08M 2025-12
Zz Pientze Pharmaceu CNY 1.55B 129.66M 2025-09